Advertisement
Advertisement
U.S. markets open in 6 hours 37 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Athersys, Inc. (ATHX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.2772-0.0228 (-7.60%)
At close: 04:00PM EDT
0.2782 +0.00 (+0.36%)
After hours: 07:58PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close0.3000
Open0.2928
Bid0.0000 x 1000
Ask0.0000 x 1200
Day's Range0.2651 - 0.2930
52 Week Range0.1700 - 1.8100
Volume6,062,949
Avg. Volume12,955,956
Market Cap73.163M
Beta (5Y Monthly)-1.26
PE Ratio (TTM)N/A
EPS (TTM)-0.3570
Earnings DateAug 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.63
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ATHX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Athersys, Inc.
    Daily – Vickers Top Buyers & Sellers for 08/09/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    20 hours agoArgus Research
View more
  • Benzinga

    Radiation Countermeasure Study Data For U.S. Defense Department Gets First Readout

    Athersys Inc (NASDAQ: ATHX) has announced the results of a radiation countermeasure study that showed intravenous MultiStem (invimestrocel) administration provided benefit in an animal model of acute radiation syndrome (ARS). The results demonstrate that the administration of MultiStem cells increased survival in treated animals compared to vehicle treatment, resulting in higher body weights in surviving animals and positive trends in the recovery of the hematopoietic system. Also Read: Athersys

  • Business Wire

    Athersys Announces Favorable Preclinical Results for MultiStem® Treatment in Defense Department Radiation Countermeasure Study and Upcoming Webinar to Review Preclinical Research With MultiStem Across Multiple Indications

    CLEVELAND, August 08, 2022--Athersys, Inc. (Nasdaq: ATHX) announces today results of a radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI), a Department of Defense research laboratory under the leadership of the Uniformed Services University of the Health Sciences, that showed intravenous MultiStem® (invimestrocel) administration provided benefit in an animal model of acute radiation syndrome (ARS). The results demonstrate that the administration

  • American City Business Journals

    Athersys hires turnaround consultant as interim CFO

    Athersys Inc., the Cleveland-based regenerative medicine company, has hired turnaround specialist Ankura Consulting Group LLC and appointed the firm's senior managing director, Kasey Rosado, as its interim chief financial officer. Athersys lost its previous CFO, Ivor Macleod, in June through a restructuring — which included cutting its workforce by as much as 70% — aimed at reducing costs and making it an attractive investment for potential financial or strategic partners. New York-based Ankura offers management consulting and expert services "at critical inflection points," including corporate restructuring, bankruptcy, dispute and litigation, according to its LinkedIn page.

Advertisement
Advertisement